both acquisitions lack a genuine strategic rationale. OPN are essentially buying a bit of revenue but at what cost? these bolt-on acquisitions will do little to rectify OPN's lack of contracts. demonstrates a complete lack of focus.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025